Atlas Trials

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Clinical trial NCT02633189 · UNKNOWN

Trial details

NCT number
NCT02633189
Sponsor
National Cancer Institute, Naples
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Non-squamous Non-small Cell Lung Cancer
Start date
2016-04-01
Primary completion
2023-12-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.